Crossmark

BAFF is a marker of hypogammaglobulinemia, neuroaxonal damage and inflammation in multiple sclerosis patients on ocrelizumab

Published Online: 2025-11-28

Authors

Chumakova, Anastasia

McKay, Lauren

Fleming, Victoria

Demetriou, Michael

Sy, Michael
License Information

Text and Data Mining valid from 2025-11-28

Version of Record valid from 2026-01-03
More Information

Article History

Received: 4 August 2025

Accepted: 11 November 2025

First Online: 28 November 2025

Declarations

:

: The study was approved by the institutional review board (UCI IRB #5318). Informed consent requirements were waived.

: The authors have no conflict of interest to disclose.

Document is current